Hostname: page-component-7bb8b95d7b-2h6rp Total loading time: 0 Render date: 2024-09-18T14:53:48.730Z Has data issue: false hasContentIssue false

EPA-1227 – Interaction Between Genetic Factors and Cannabis Use in Schizophrenia: Phenotypic, Environmental and Genetic Approach

Published online by Cambridge University Press:  15 April 2020

J. Mallet
Affiliation:
Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris (AP-HP) Hôpital Louis Mourier, Colombes, France
N. Ramoz
Affiliation:
Centre Psychiatrie et Neurosciences, INSERM U894, Paris, France
P. Gorwood
Affiliation:
Centre Psychiatrie et Neurosciences, INSERM U894, Paris, France
C. Dubertret
Affiliation:
Service de Psychiatrie et Addictologie, Assistance Publique-Hôpitaux de Paris (AP-HP) Hôpital Louis Mourier, Colombes, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Identifying schizophrenia vulnerability factors requires testing specific hypotheses concerning etiopathogenic models, candidate genes, and environmental factors involved. We hypothesized that patients developing schizophrenia after using regularly cannabis represent an homogenous phenotypic entity which could result from a specific interaction between genetic polymorphisms (SNPs) of CNR1, CNR2 and COMT genes and cannabis use (an environmental factor intervening lately in the neurodevelopment).

Objectives:

The main objective was to confirm that patients using cannabis before the onset of schizophrenia had fewer markers of early-neurodevelopmental impairment. The secondary objective was to identify a gene environment interaction in this subset of patients.

Methods:

Patients were prospectively included and underwent a standardized interview and an evaluation of cognitive functions and neurological soft signs. Blood and saliva samples were collected. For the case-case genetic study, those patients were pooled with patients included in a cannabisdependent schizophrenic-patients cohort. Eight CNR1, CNR2 and COMT SNPs were analyzed.

Results:

We included 61 patients in the clinical part. Regular cannabis users before the onset of the disorder had fewer neurological soft signs, less cognitive impairment and a different clinical symptomatology. For the genetic part 26 patients were added to the 57 patients from the clinical part (4 non Caucasian patients excluded). Results were in favor of a gene environment interaction for rs1049353 of CNR1.

Conclusions:

We found that regular cannabis users before the onset of schizophrenia had less neurodevelopmental impairment. In this subset of patients, cannabis could play a causal role in a gene environment interaction leading to schizophrenia.

Type
FC02 - Free Communications Session 02: Neurobiology of schizophrenia
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.